Researcher Profile

Researcher Profile

Andrea Manni, MD

Andrea Manni, MD

Professor, Department of Medicine
Chief, Division of Endocrinology and Diabetes
Scientific Program:Cancer Control

Research Interests

Dr. Andrea Manni joined the faculty of Penn State College of Medicine in 1982 and has more than 200 scholarly publications. His primary research interest has been breast cancer with a focus on endocrine determinants of tumor biology, autocrine/paracrine factors mediating hormonal effects and interactions between hormones and polyamines in tumor control.

Dr. Manni’s research teams were among the first to demonstrate the potent antitumor activity of the antiestrogen Tamoxifen in women with hormone-responsive breast cancer. Recently, he has focused on breast cancer prevention through dietary manipulations with omega-3 fatty acids (n-3FA) in conjunction with antiestrogens. His most recent work has indicated that among n-3FA, docosahexaenoic acid (DHA) may be the most potent in selectively reducing breast cancer risk in obese postmenopausal women. He has lectured extensively on this topic nationally and internationally.

Throughout his career, Dr. Manni has served on research grant review committees such as NIH and Department of Defense study sections. He has been an editor of the Journal of Clinical Endocrinology and Metabolism, the premiere clinical journal of the Endocrine Society. He has also been on the editorial boards of several journals with a focus on endocrine oncology.

  • Breast Neoplasms
  • Neoplasms
  • Polyamines
  • Therapeutics
  • Growth
  • Hormones
  • Tamoxifen
  • Eflornithine
  • Estrogens
  • Estrogen Receptor Modulators
  • Prolactin
  • Methylnitrosourea

Recent Publications


El-Bayoumy, K & Manni, A 2020, 'Customized Prevention Trials Could Resolve the Controversy of the Effects of Omega-3 Fatty Acids on Cancer', Nutrition and cancer, vol. 72, no. 2, pp. 183-186.
Sun, YW, Xu, H, Benitez, G, Chen, KM, Stanley, A, Stanley, B, Zhu, J, Thompson, H, Manni, A & El-Bayoumy, K 2019, 'Omega-3 Fatty Acids Responsive Proteins and Reduction in Breast Density in Obese Postmenopausal Women', Journal of Proteome Research, vol. 18, no. 9, pp. 3461-3469.


Manni, A, El-Bayoumy, K & Thompson, H 2018, 'Docosahexaenoic acid in combination with dietary energy restriction for reducing the risk of obesity related breast cancer', International journal of molecular sciences, vol. 19, no. 1, 28.


Manni, A, Richie, JP, Schetter, SE, Calcagnotto, A, Trushin, N, Aliaga, C & El-Bayoumy, K 2017, 'Stearoyl-CoA desaturase-1, a novel target of omega-3 fatty acids for reducing breast cancer risk in obese postmenopausal women', European Journal of Clinical Nutrition, vol. 71, no. 6, pp. 762-765.


Skibinski, CG, Das, A, Chen, KM, Liao, J, Manni, A, Kester, M & El-Bayoumy, K 2016, 'A novel biologically active acid stable liposomal formulation of docosahexaenoic acid in human breast cancer cell lines', Chemico-Biological Interactions, vol. 252, pp. 1-8.
Manni, A & El-Bayoumy, K 2016, 'Do omega-3 fatty acids reduce the risk of breast cancer in postmenopausal obese women?', Expert Review of Endocrinology and Metabolism, vol. 11, no. 5, pp. 365-367.
Sandhu, N, Schetter, SE, Liao, J, Hartman, TJ, Richie, JP, McGinley, J, Thompson, HJ, Prokopczyk, B, DuBrock, C, Signori, C, Hamilton, C, Calcagnotto, A, Trushin, N, Aliaga, C, Demers, LM, El-Bayoumy, K & Manni, A 2016, 'Influence of obesity on breast density reduction by omega-3 fatty acids: Evidence from a randomized clinical trial', Cancer Prevention Research, vol. 9, no. 4, pp. 275-282.
for the VALUES Consortium 2017, 'The relationship between oestrogen and executive functioning in ALS females with emerging Frontotemporal Lobar Degeneration (FTLD) supports a neuroendocrine model of FTLD attenuation', Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, vol. 18, no. 1-2, pp. 74-85.
Manni, A, El-Bayoumy, K, Skibinski, CG, Thompson, HJ, Santucci-Pereira, J, Bidinotto, LT & Russo, J 2016, The role of omega-3 fatty acids in breast cancer prevention. in Trends in Breast Cancer Prevention. Springer International Publishing, pp. 51-81.

Clinical Trials Search

Children (age < 18 years)
Adults (age >= 18 years)